Медико-биологический
информационный портал
для специалистов
 
Medline.ru

СОДЕРЖАНИЕ ЖУРНАЛА:
Физико-химическая биология

Клиническая медицина

Профилактическая медицина

Медико-биологические науки


АРХИВ:

Фундаментальные исследования

Организация здравохраниения

История медицины и биологии



Последние публикации

Поиск публикаций

Articles

Архив :  2000 г.  2001 г.  2002 г. 
               2003 г.  2004 г.  2005 г. 
               2006 г.  2007 г.  2008 г. 
               2009 г.  2010 г.  2011 г. 
               2012 г.  2013 г.  2014 г. 
               2015 г.  2016 г.  2017 г. 
               2018 г.  2019 г.  2020 г.  2021 г.  2022 г.  2023 г. 

Редакционная информация:
        Опубликовать статью
        Наша статистика


 РЕДАКЦИЯ:
Главный редактор

Заместители главного редактора

Члены редколлегии
Специализированные редколлегии


 УЧРЕДИТЕЛИ:
Институт теоретической и экспериментальной биофизики Российской академии наук.

ООО "ИЦ КОМКОН".




Адрес редакции и реквизиты

199406, Санкт-Петербург, ул.Гаванская, д. 49, корп.2

ISSN 1999-6314

Российская поисковая система
Искать: 


«
Vol. 12, Art. 80 (pp. 959-979)    |    2011       
»

Laboratory markers of chronic myeloid leukemia
Syasina T.V., *Bessmeltsev S.S., Kozlov A.V.

St-Petersburg Medical Academy of Postgraduate Studies, Russia; St-Petersburg,191015, Kirochnaya str., 41;

*- Russian Research Institute of Hematology and Transfusiology, St-Petersburg



Brief summary

The modern diagnostic level of myeloid neoplasms expect the use of a complex various laboratory methods. In this review, we pose the diagnostic algorithm of chronic myeloid leukemia, which is usually considered the standard for this disease. Algorithm includes the study of the peripheral blood, bone marrow, holding molecular cytogenetic and immunocytochemical analysis, and, if necessary, histological study bone marrow aspirate and biopsies. In depend on the disease phase given the characteristic features of the results referred above research methods. Consider various diagnostic criteria, according in modern literature to determine the chronic phase, accelerated phase and blast phase of chronic myeloid leukemia and used at present the doctors of different scientific groups in therapeutic practice, particularly: criteria used by the WHO classification, criteria used by The University of Texas M. D. Anderson Cancer Center and criteria used at the European Leukemia Net. New approaches to assessment of the disease heaviness, the rate of development and effectiveness therapy with tyrosine kinase inhibitors employing markers of apoptosis actively researching in last 10-15 years. Authentically known that the inhibition of apoptosis may be the mechanism by which tumor cells become resistant to drugs. Factors involved in the regulation of apoptosis process, are regarded as the main cellular objectives targeted therapy. The study in patients with chronic myeloid leukemia apoptotic reactions in the bone marrow cells of apoptosis induction in vitro constitute to be a perspective direction, so far as monitoring dynamics of this process in during the treatment may be marker of effectiveness therapy and relieve in selection rational treatment of disease.


Key words

chronic myelogenous leukemia, criteria disease phase, diagnostic algorithm, laboratory markers, apoptosis.





(The article in PDF format. For preview need Adobe Acrobat Reader)



Open article in new window

Reference list

1. Abdylkadirov K.M., Bessmelcev S.S., Rykavicin O.A. Hronicheskii mieloleikoz. – SPb: “Specialnaya Literatyra”, 1998.- 464 s.


2. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrcm-Lindberg E, Tefferi A, Bloomfield CD. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes// Blood. – 2009. – vol.114, №5. – P.937 – 951.


3. J. D. Rowley. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining// Nature. – 1973. – vol. 243, № 5405. – P. 290–293.


4. Ried T. Cytogenetics – In color and digitalized// N Engl JMed. – 2004. – vol.350(16). – P.1597-1600.


5. G. Q. Daley., R. A. Van Etten., D. Baltimore. Induction of chronic myelogenous leukemia in mice by the P210(bcr/abl) gene of the Philadelphia chromosome// Science. – 1990. – vol. 247, № 4944. – P.824–830.


6. Hochhaus A, La Rosie P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance// Leukemia. – 2004. – Vol.18, № 8. – P.1321-1331.


7. Cortes J., O`Dwyer M.E. Clonal evolution in chronic myelogenous leukemia// Hematol Oncol Clin North Am. – 2004. – Vol.8(3). – P.671–684.


8. Savage D.G., Szydlo R.M., Goldman J.M. Clinical features at diagnosis in 430 patients with chronic myeloid leukemia seen at a referral centre over a 16-year period// Br J Haematol. – 1997. – Vol.96. – P.111–116.


9. Koffi KG, Nanho DC, N'dathz E, Kouehion P, Dissieka R, Attia A, Mozard K, Tolo A, Boidy K, Meiti N, Ayemou R, Sekongo M, Tea N, Sanogo I. The Effect of Imatinib Mesylate for Newly Diagnosed Philadelphia Chromosome-Positive, Chronic-Phase Myeloid Leukemia in Sub-Saharan African Patients: The Experience of Cfte d'Ivoire // Adv Hematol. – 2010. – Vol.2010. – Article ID 268921, 6 pages. doi:10.1155/2010/268921 114.


10. Hehlmann R, Berger U, Pfirrmann M, et al. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.// Leukemia. - 2003. - Vol.17. - P. 1529-1537.


11. Fausel C. Targeted chronic myeloid leukemia therapy: seeking a cure// J Manag Care Pharm. – 2007. – Vol.13, № 8. – P.8-12.


12. M. E. O’Dwyer., M. J. Mauro., B. J. Druker. Recent advancements in the treatment of chronic myelogenous leukemia// Annual Review of Medicine. – 2002. – vol. 53. – P.369–381.


13. Lomaia E.G., Motorin D.V., Romanova E.G., Zarickii A.U. Hronicheskii mieloleikoz – do i posle primeneniya imatiniba// Onkogematologiya. – 2009. – №2. – S.4-17.


14. Siu L.L., Ma E.S., Wong W.S., Chan M.H., Wong K.F. Application of tri-colour, dual fusion fluorescence in situ hybridization (FISH) system for the characterization of BCRABL1 fusion in chronic myelogenous leukaemia (CML) and residual disease monitoring// BMC Blood Disord. – 2009. – Vol.9, № 4 – doi:10.1186/1471-2326-9-4 URL: http://www.biomedcentral.com/1471-2326/9/4 (data obrasheniya 22.10.2011).


15. Lygovskaya S. A., Morozova V. T., Pochtar M. E. Laboratornaya diagnostika leikozov. Tver: "Gybernskaya medicina". – 1999. – S.29-34.


16. Posobie: Moiseev S.I., Zarickii A.U., Salogyb G.N., pod red. A.A.Ganapiev. Hronicheskie mieloproliferativnie zabolevaniya. Klassifikaciya, diagnostika i lechenie. S-Peterbyrg, 2005. – S.10-11.


17. Yin C.C., Medeiros L.J., Bueso-Ramos C.E. Recent advances in the diagnosis and classification of myeloid neoplasms – comments on the 2008 WHO classification// Int J Lab Hematol. – 2010. – Vol. 32, №5. – P.461-476.


18. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms// Blood. – 2002. – Vol.100. – P.2292–2302.


19. Cortes J.E., Talpaz M., O’Brien S., Faderl S., Garcia-Manero G., Ferrajoli A., Verstovsek S., Rios M.B., Shan J., Kantarjian H.M. Staging of chronic myeloid leukemia in the imatinib era. An evaluation of the World Health Organization proposal// Cancer. – 2006. – Vol.106. – P.1306–1315.


20. Baccarani M., Saglio G., Goldman J. et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of European Lukemia Net// Blood. – 2006. – Vol.108. – P.1809–20.


21. Schoch C., Haferlach T., Kern W. et al. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate// Leukemia. – 2003. – Vol.17. – P.461–463.


22. Kantarjian H., Sawyers C., Hochhaus A., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia// N Engl J Med. – 2002. – Vol.346. – P.645–652.


23. Glyzman D.F., Sklyarenko L.M., Nadgornaya V.A., Ivanovskaya T.S. Sovremennaya laboratornaya diagnostika mieloproliferativnih novoobrazovanii/ Med. gaz. Zdorove ykraini. – 2011 – № 1(14) - S. 26-27.


24. ISCN (1995): An International System for Human Cytogenetic Nomenclature, Mitelman, F (ed); S. Karger, Basel, 1995


25. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., Harris N.L., Le Beau M.M., Hellström-Lindberg E., Tefferi A., Bloomfield C.D. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes// Blood. – 2009. – Vol.114, №5. – P.937-951.


26. Kantarjian H.M., Dixon D., Keating M.J. et al. Characteristic of accelerated disease in chronic myelogenous leukemia// Cancer. – 1988. – Vol.61. – P.1441–1446.


27. Yaghmaie M., Ghaffari S.H., Ghavamzadeh A., Alimoghaddam K., Jahani M., Mousavi S.A., Irvani M., Bahar B., Bibordi I. Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia//Arch Iran Med. – 2008. – Vol.11, № 3. – P.247-251.


28. Jones D., Luthra R., Cortes J. et al. BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changed in determining the phenotype of Philadelphia chromosome-positive leukemias// Blood. – 2008. – Vol.15(112). – P.5190–5192.


29. Lee W.I., Kantarjian H., Glassman A., Talpaz M., Lee M.S. Quantitative measurement of BCR/abl transcripts using real-time polymerase chain reaction// Ann Oncol. – 2002. – Vol.13(5). – P.781-788.


30. Glyzman D.F., Sklyarenko L.M., Nadgornaya V.A. Opyholi krovetvornoi i limfoidnoi tkanei (citomorfologiya, immynocitohimiya, algoritmi diagnostiki). — K.: DIA, 2008.—196s.


31. Lygovskaya S.A., Pochtar M.E. Gematologicheskii atlas. 2004. – izd.«Triada» . – S.83- 99.


32. Glyzman D.F., Sklyarenko L.M., Nadgornaya V.A., Ivanovskaya T.S. Sovremennaya laboratornaya diagnostika mieloproliferativnih novoobrazovanii/ Med. gaz. Zdorove ykraini. – 2011 – № 2(15) - S. 30-31.


33. Theml H., Diem H., Haferlach T. Color atlas of hematology. – 2004. – P.114-121.


34. Osipova E.U. Kletochnie modeli dlya ocenki yrovnya i haraktera apoptoza kletok krovi cheloveka. Avtoref. dis. kand. biol. nayk. – M., 2003 – 45 S.


35. Pospelova T.I., Loseva M.I., Kovinev I.B. i dr. Osnovi opyholevoi progressii gemoblastozov // Bul. SO RAMN. – 2004. – T. 112, № 2. – S. 73—76.


36. Ballard K.S., Homesley H.D., Hodson C., Presant C.A., Rutledge J., Hallquist A., Perree M. Endometrial carcinoma in vitro chemosensitivity testing of single and combination chemotherapy regimens using the novel microculture kinetic apoptosis assay: implications for endometrial cancer treatment // J. Gynecol. Oncol. – 2010. – Vol.21, № 1. – P.45 – 49.


37. Bessmelcev S.S., Kozlov A.V., Syasina T.V., Ydaleva V.U. Sravnitelnaya ocenka metodov opredeleniya apoptoticheskoi aktivnosti kletok kostnogo mozga y bolnih hronicheskim mieloleikozom (flyorescentnaya mikroskopiya i protochnaya citometriya) // Fyndamentalnie issledovaniya – 2011. – №10. – S. 33-36.


38. Kozlov A.V., Syasina T.V., Bessmelcev S.S., Ydaleva V.U., Zarickii A.U. Apoptoticheskaya aktivnost kletok kostnogo mozga y bolnih hronicheskim mieloleikozom na fone lecheniya imatinibom (glivekom)// MEDLINE.RU: setevoi jyrnal. 2010. tom 11, S. 268-283. URL: http://www.medline.ru/public/art/tom11/art21.html.


39. Bellisola G., Della Peruta M., Vezzalini M., Moratti E., Vaccari L., Birarda G., Piccinini M., Cinque G., Sorio C. Tracking infrared signatures of drugs in cancer cells by Fourier transform microspectroscopy // Analyst. – 2010. – Vol.135, № 12. – P. 3077 – 3086.



Свидетельство о регистрации сетевого электронного научного издания N 077 от 29.11.2006
Журнал основан 16 ноября 2000г.
Выдано Министерством РФ по делам печати, телерадиовещания и средств массовых коммуникаций
(c) Перепечатка материалов сайта Medline.Ru возможна только с письменного разрешения редакции

Размещение рекламы

Rambler's Top100